TITLE

GPs should join debate on potential risk versus reward of obesity drug

AUTHOR(S)
Castaneda, Reynald
PUB. DATE
October 2014
SOURCE
New Zealand Doctor;10/8/2014, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the debate by general practitioners (GP) and clinicians in New Zealand on the risks and reward of the obesity drug phentermine.
ACCESSION #
98892766

 

Related Articles

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • The Straight Dope On Weight-Loss Drugs. Fentress, Debbie; Agnew, Bruce // Diabetes Forecast;Apr2002, Vol. 55 Issue 4, p51 

    Provides information on weight-loss drugs, Xenical, Meridia and phentermine. Overview of studies on the drugs; Side effects of weight loss drugs; Contents of the drugs. INSET: Beware herbal remedies.

  • Options for treating obesity. Campbell, Ian // GP: General Practitioner;4/26/2002, p70 

    Focuses on the options for general practitioners in treating obesity. Effectiveness of anti-obesity drugs; Requirements for drug administration; Importance of setting realistic targets.

  • Long-Term Results of Drug Treatment for Obesity. SLAWSON, DAVID // American Family Physician;3/1/2014, Vol. 89 Issue 5, p389 

    The article presents answers to a question on whether weight loss medications are effective as long-term treatment for obesity.

  • New experimental drug helps obese patients lose weight.  // New York Amsterdam News;02/25/99, Vol. 90 Issue 9, p14 

    Highlights the results of a study conducted at Baylor College of Medicine in Houston, Texas indicating the potency of orlistat to promote weight loss among obese patients. Need for the combination of moderate-calorie diet; Mechanism of the drug's action; Adverse reactions.

  • 5 that work. Nachatelo, Melissa // Natural Health;May/Jun2001, Vol. 31 Issue 4, p70 

    Presents information about different natural diet supplements used in the management of obesity. Green tea; Ephedra; Chromium.

  • FDA Warning on Chinese Diet Pills Containing Fenfluramine.  // FDA Consumer;Sep/Oct2002, Vol. 36 Issue 5, p7 

    Reports on warnings about Chinese weight-loss products from the U.S. Food and Drug Administration. Risks from Chaso Diet Capsules and Chaso Genpi; Deaths in Japan; Danger of the toxic ingredient, aristolochic acid; Lethal combination of fenfluramine and phentermine.

  • Focus On Orlistat: A Nonsystemic Inhibitor Of Gastrointestinal Lipase For Weight Reduction In The Management Of Obesity. Chow, Moses S.S.; Reddy, Prabashni // Formulary;Oct98, Vol. 33 Issue 10, p943 

    Discusses orlistat, a nonsystemic inhibitor of gastrointestinal lipase for weight reduction in the management of obesity. Chemistry and pharmacology; Pharmacokinetics; Clinical trials; Guidelines for obesity therapy; Adverse effects; Drug interaction; Dosage. INSET: Formulary Considerations.

  • Profit in Loss. Wellner, Alison Stein // American Demographics;Jul2000, Vol. 22 Issue 7, p46 

    Discusses the development of the XeniCare program offered to patients using the Roche Laboratories' Xenical prescription obesity drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics